Does the Syk-kinase inhibitor R406 impair platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies?
Syk inhibitors may be of therapeutic interest in the treatment of HIT by reducing HIT antibodies-mediated platelet activation and monocyte procoagulant activity.
Results indicate that the anti-immobility effect of ascorbic acid and ketamine in TST may involve an activation of GABAA receptors and a possible inhibition of GABAB receptors.